Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Purchased by Addison Advisors LLC

Addison Advisors LLC boosted its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 863.0% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 14,608 shares of the company’s stock after purchasing an additional 13,091 shares during the quarter. Addison Advisors LLC’s holdings in Takeda Pharmaceutical were worth $208,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in TAK. Millennium Management LLC grew its holdings in shares of Takeda Pharmaceutical by 87.1% in the 2nd quarter. Millennium Management LLC now owns 4,346,151 shares of the company’s stock worth $56,239,000 after acquiring an additional 2,023,707 shares during the period. Van ECK Associates Corp boosted its position in Takeda Pharmaceutical by 6.6% during the third quarter. Van ECK Associates Corp now owns 2,175,236 shares of the company’s stock worth $30,149,000 after purchasing an additional 134,407 shares in the last quarter. Cowen AND Company LLC acquired a new stake in Takeda Pharmaceutical in the second quarter valued at $6,866,000. Summit Global Investments increased its position in shares of Takeda Pharmaceutical by 86.0% in the third quarter. Summit Global Investments now owns 415,558 shares of the company’s stock valued at $5,909,000 after buying an additional 192,143 shares in the last quarter. Finally, Sei Investments Co. boosted its position in shares of Takeda Pharmaceutical by 6.7% in the 1st quarter. Sei Investments Co. now owns 372,975 shares of the company’s stock worth $5,181,000 after buying an additional 23,525 shares in the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Price Performance

Shares of NYSE TAK opened at $13.66 on Tuesday. The company has a current ratio of 1.28, a quick ratio of 0.77 and a debt-to-equity ratio of 0.64. The stock has a market cap of $43.45 billion, a price-to-earnings ratio of 23.54, a PEG ratio of 0.26 and a beta of 0.54. The company’s 50-day moving average price is $14.38 and its 200 day moving average price is $13.82. Takeda Pharmaceutical Company Limited has a 52 week low of $12.57 and a 52 week high of $15.08.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.